Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP0), a fast-growing AI health technology company, has unveiled a comprehensive multi-vertical expansion strategy aimed at transforming into a leading global AI health-tech enterprise. The company’s growth plan centers on three key platforms: Clinical-Trial Optimization, Consumer Digital Health, and the continued commercialization of its clinically validated SmartHealth AI Stations. At the core of the strategy is the SmartHealth AI Station, a contactless screening system that uses multispectral imaging and proprietary AI to detect a range of health indicators, including vital signs, impairment from drugs or alcohol, fatigue, and mental health concerns. Independent, multi-center clinical trials have validated the system’s accuracy at approximately 95%, positioning it for deployment in enterprise safety, hospital triage, and public health programs worldwide. The first major expansion is the development of a Clinical-Trial AI Platform, designed to serve as a near-term growth driver. This SaaS-based solution leverages adaptive AI to simulate, optimize, and predict outcomes across multi-site clinical trials. It will support trial simulation, cross-trial learning, cost and outcome modeling, and full regulatory traceability. With the global clinical trials market projected to reach $123.5 billion by 2030—growing at a compound annual rate of about 6.5%—this platform is poised to capture significant demand from pharmaceutical and biotech companies. The second platform is a direct-to-consumer mobile application that will allow users to monitor vital signs using only their smartphone’s camera. Built on Predictmedix’s patented imaging technology, the app targets the rapidly expanding digital health and telehealth sectors, enabling individuals to track their health remotely and proactively. Dr. Rahul Kushwah, Chief Operating Officer of Predictmedix, emphasized the strategic value of this diversification: “Our validated SmartHealth technology provides the data, AI engine, and market credibility to scale across enterprise, clinical research, and consumer segments. This multi-vertical approach is designed to diversify revenue streams and support sustainable long-term growth for our shareholders.” The company is currently assessing regulatory pathways in key markets, including Southeast Asia, and plans to pursue formal medical device certifications to enable broader global deployment. Predictmedix continues to build momentum through pilot programs, strategic partnerships, and product validations. The company’s technology has already demonstrated real-world applicability in health screening and remote patient monitoring. As with all forward-looking statements, the company cautions that actual results may differ due to risks including regulatory delays, intellectual property challenges, market competition, economic conditions, and unforeseen developments such as public health crises. The company disclaims any obligation to update forward-looking information except as required by law. For more information, including details on recent validations and partnerships, visit www.predictmedix.com/press-releases.